December 11, 2015
Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Dr. William J. Polvino steps down as President and CEO after more than six years in the role.
93% of patients had full or partial cyst resolution at 12 months. No post-operative infections reported during follow-up period. No fractures reported during the follow-up period


Professor wants to develop a radioactive precision missile to target brain cancer
21. February 2020
New test exposes dangerous moles
14. February 2020
Asthma is programmed early in life
7. February 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge